Articles

iCarly Black “Rockin’ the Look” Messenger Bag (Black)

By an0201toniolyons on  From hot-shoes-4458.eu.gp
iCarly Black “Rockin’ the Look” Messenger Bag (Black) See more>>> Gdc size approx 16inch H x 12in W x 4.5in D (40cm x 30cm x 11.5cm) See more>>> Find More Gdc Products Price: $ 16.95 Show more>>> A NEW RESEARCH OF GDC-0879 FOR B-RAF KINASE Article by Katewinslet INTRODUCTION The MAP kinase pathway which originates from RAS and moves through raf and other kinases plays a very significant role in maintaining the normal cellular responses. An...Read Full Story

BELINOSTAT (PXD101) – INHIBITS THE CANCEROUS GROWTH

By CedricSandford on  From hdacblog.com
INTRODUCTIONCancers are usually an outcome of the alternations in the genetic material. Genetic and epigenetic changes regulate the alternations in the DNA. The genetic events include rearrangement of chromosomes, amplification of genetic material, mutations within DNA etc. These events influence the expression of tumor suppressor genes. They stimulate the expression of the products of proto-oncogenes. Epigenetic changes however influence the expression of genes in a mutation independent...Read Full Story

CUDC-101- A SINGLE INHIBITOR WITH MULTIPLE EFFECTS

By CedricSandford on  From hdacblog.com
INTRODUCTIONDifferent cases of cancers are associated with modifications in the tyrosine kinase receptors and histone deacetylases. The malfunctioning of these proteins leads to hampered cellular responses. Various inhibitors which target the tyr kinase receptors have been designed. The success rate of these inhibitors against cancer has been rated to be low as cancers are dynamic in nature and they also offer resistance to these inhibitors. The causes of cancer may be different at different...Read Full Story

AV-951 – THE ANTI-ANGIOGENIC DRUG

By elinacherry on
ANGIOGENESIS AND AV-951: Angiogenesis as a process is very crucial for the progression of tumors. Not only cells proliferate uncontrollably in cancers, they require a better vascular system to support these new and upcoming cells. Hence the development of anti-angiogenesis compounds is seen as an attractive approach that can deal with one facet of tumor biology successfully. The most commonly linked pathway to angiogenesis is Vascular Endothelial Growth Factor (VEGF) pathway and the...Read Full Story

SORAFENIB – SHOWS MULTIFARIOUS EFFECTS IN OSTEOSARCOMA CELL LINES

By CedricSandford on  From hdacblog.com
INTRODUCTIONReceptor tyrosine kinases activate two primary pathways which are PI3K pathway which moves down through AKT and MAPK pathway which passes down through ERK1/2. Many cancers are associated with the hyperactivation of the MAPK pathway. This pathway starts from Ras and moves through Raf, MEK1/2 and ERK1/2 (the final effector molecule). Scientists have used sophisticated techniques like high throughput screening methods to discover novel molecules like Sorafenib, which can target this...Read Full Story

DROXINOSTAT – MAKES A CANCEROUS CELL SENSITIVE TO DEATH SIGNALS

By CedricSandford on  From hdacblog.com
INTRODUCTIONHistone deacetylases play a vital role in stimulating the ocogenic pathways within a normal cell and hence transforming it into a cancerous cell. Research has shown that by controlling the action of these histone deacetylases, we can control cancer. Various inhibitors to HDACs, have been designed which control cancer in different ways. Droxinostat is one such HDAC inhibitor which sensitizes the cancerous cells to ligands of death receptors.DROXINOSTAT: MODE OF ACTIONFas and TRAIL...Read Full Story

PANOBINOSTAT (LBH-589) – EFFECTIVE IN LARGE NUMBER OF TUMORS

By CedricSandford on  From hdacblog.com
INTRODUCTIONThe set of enzymes which catalyze the removal of acetyl group from both histone (N terminal lysine residues) and non histone proteins are together grouped as Histone deacetylases. These HDAC enzymes regulate a large number of vital processes within the cell. HDAC inhibitors are designed in such a manner that they can regulate these cellular functions. Panobinostat is one such inhibitor of HDAC, which promises a treatment against several cancers [1].PANOBINOSTAT: ALTERS GENE...Read Full Story

MS-275 (ENTINOSTAT) – REVERTS THE EPIGENETIC SILENCING INDUCED CHANGES

By CedricSandford on  From hdacblog.com
INTRODUCTIONThe distribution and amounts of HDACs (which deacetylate the lysine residues within the histone proteins) within the brain is less understood. HDACs play a major role in epigenetic silencing and suppression of TSG genes. The different isoforms of HDACs perform specific functions at different locations within brain. Experiments were carried with PET to study the levels of expression of HDACs. Few HDACinhibitors target the epigenetic mechanism and hence control a large number of...Read Full Story

ITF2357 (GIVINOSTAT) – POTENTIATES A CONCENTRATION DEPENDENT EFFECT ON MYELOMA CELLS

By CedricSandford on  From hdacblog.com
INTRODUCTIONThe histone deacetylases remove the acetyl group from the lysine residues. Due to this the chromatin becomes more compact and the genes are less accessible to the transcription factors. The inhibitors to HDACs unravel the genetic material making it more accessible to the set of enzymes meant for transcription. This promotes the transcription followed translation of those genes. It is also potent enough to revert the inflammatory response.ITF2357 INTERFERES WITH THE PROCESS OF...Read Full Story

AZD2281: THE FIRST PARP INHIBITOR

By elinacherry on
PARP INHIBITION AND AZD2281: As many disease conditions are more dependent on PARP enzymes, the targeting of PARP and its inhibition becomes an attractive approach for treating those conditions and cancer is one such example where this approach has been tested successfully. Most of these inhibitors are developed to spare the normal cells which do not often go for DNA replication while killing cancer cells where the deficiency of genes associated with DNA repair enzymes leaves them vulnerable...Read Full Story
More From Zimbio
Zimbio Entertainment
Copyright © 2012 - Zimbio, Inc. Some rights reserved. Coming soon: Livingly
Share
. . .
Follow
. . .